The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Self-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J. (2003) · Nature · doi:10.1038/nature02067 · Cited by 801
Kitada, S., Andersen, J., Akar, S., Zapata, J. M., Takayama, S., Krajewski, S., Wang, H.-G., Zhang, X., Bullrich, F., Croce, C. M., et al. (1998) · Blood · doi:10.1182/blood.v91.9.3379 · Cited by 651
Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells
Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S.-I., Akashi, K., & Korsmeyer, S. J. (2005) · Science · doi:10.1126/science.1106114 · Cited by 574
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., & Reed, J. C. (1998) · Blood · doi:10.1182/blood.v91.3.991 · Cited by 365
Self-citationMutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327 · cited 5×
“Since Mcl-1 is phosphorylated on a number of different residues in response to a variety of stimuli (Domina et al., 2000, 2004; Inoshita et al., 2002), turnover of this short-lived antiapoptotic protein is likely subject to regulation by a number of different signaling pathways.”
BackgroundInfluentialTherapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia
Milella, M., Kornblau, S. M., Estrov, Z., Carter, B. Z., Lapillonne, H., Harris, D., Konopleva, M., Zhao, S., Estey, E., & Andreeff, M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12807 · Cited by 312
Craig, R. (2002) · Leukemia · doi:10.1038/sj.leu.2402416 · Cited by 266
Yu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., & Grant, S. (2003) · Blood · doi:10.1182/blood-2003-03-0737 · Cited by 259
Self-citationAichberger, K. J., Mayerhofer, M., Krauth, M.-T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., et al. (2005) · Blood · doi:10.1182/blood-2004-02-0749 · Cited by 253
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
Phosphorylation and Inactivation of Myeloid Cell Leukemia 1 by JNK in Response to Oxidative Stress
Inoshita, S., Takeda, K., Hatai, T., Terada, Y., Sano, M., Hata, J., Umezawa, A., & Ichijo, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207951200 · Cited by 233
Taniai, M., Grambihler, A., Higuchi, H., Werneburg, N., Bronk, S. F., Farrugia, D. J., Kaufmann, S. H., & Gores, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2770 · Cited by 218
Self-citationA genome-based strategy uncovers frequent BRAF mutations in melanoma
Pollock, P. M., & Meltzer, P. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00089-2 · Cited by 160
Domina, A. M., Smith, J. H., & Craig, R. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000915200 · Cited by 93
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
Chandra, J., Hackbarth, J. S., Le, S. B., Loegering, D. A., Bone, N. D., Bruzek, L. M., Narayanan, V. L., Adjei, A. A., Kay, N. E., Tefferi, A., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0562 · Cited by 73
Self-citationYu, C., Rahmani, M., Almenara, J. A., Sausville, E. A., Dent, P., & Grant, S. (2003) · Oncogene · doi:10.1038/sj.onc.1207248 · Cited by 70
Self-citationMeng, X. W., Chandra, J., Loegering, D. A., Becelaere, K. V., Kottke, T. J., Gore, S. D., Karp, J. E., Sebolt-Leopold, J., & Kaufmann, S. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304793200 · Cited by 58
Self-citationMoshynska, O., Sankaran, K., Pahwa, P., & Saxena, A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh122 · Cited by 57
Dhillon, A. S., Meikle, S., Peyssonnaux, C., Grindlay, J., Kaiser, C., Steen, H., Shaw, P. E., Mischak, H., Eychène, A., & Kölch, W. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.1983-1993.2003 · Cited by 51
Boucher, M.-J., Morisset, J., Vachon, P. H., Reed, J. C., Lain�, J., & Rivard, N. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20001201)79:3<355::aid-jcb20>3.0.co;2-0
Cited by
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Self-citationLiu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Self-citationWilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240
Cell death-based treatment of lung adenocarcinoma
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768
Metadata
- Authors
- Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A.
- Venue
- Oncogene
- Published
- 2005-06-27
- Volume
- 24
- Issue
- 46
- Pages
- 6861-6869
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2082777374
- Cited by
- 277
- References
- 30
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.